# Neoadjuvant Treatment in Resectable Pancreatic Cancer

> **NCT01900327** · PHASE3 · TERMINATED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 32 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **RADIATION:** External Beam Radiation
- **DRUG:** Gemcitabine neoadjuvant
- **PROCEDURE:** Surgery
- **DRUG:** Gemcitabine adjuvant

## Key facts

- **NCT ID:** NCT01900327
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2016-11-22
- **Final completion:** 2017-07
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Recruitment failure
- **Last updated:** 2018-05-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900327, "Neoadjuvant Treatment in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01900327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*